Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 5/20 | 0.47 |
| ▸ | CNR1 | P21554 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17558100 | 1.00 | TSHR (0.47) | TSHRCNR2CNR1ALDH1A1NR5A1 | |
| SCHEMBL17558159 | 0.90 | CNR1 (0.47) | CNR2CNR1ALDH1A1NR5A1 | |
| SCHEMBL17558160 | 0.90 | CNR1 (0.47) | CNR2CNR1ALDH1A1NR5A1 | |
| SCHEMBL15522362 | 0.89 | NR5A1 (0.53) | TSHRCNR2ALDH1A1NR5A1MEN1 | |
| SCHEMBL30775079 | 0.89 | NR5A1 (0.53) | TSHRCNR2ALDH1A1NR5A1MEN1 | |
| SCHEMBL3682775 | 0.89 | NR5A1 (0.53) | TSHRCNR2ALDH1A1NR5A1MEN1 | |
| SCHEMBL135802 | 0.89 | NR5A1 (0.53) | TSHRCNR2ALDH1A1NR5A1MEN1 | |
| SCHEMBL31442492 | 0.82 | PPARA (0.49) | MEN1KMT2A | |
| SCHEMBL17577604 | 0.82 | CNR1 (0.48) | CNR2CNR1 | |
| SCHEMBL17558117 | 0.81 | MGLL (0.54) | CNR2CNR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3188760-B1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2023-12-06 | — | — | EP | disclosed |
| US-10844002-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2020-11-24 | — | — | US | disclosed |
| US-20190002393-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2019-01-03 | — | — | US | disclosed |
| US-10125092-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2018-11-13 | — | — | US | disclosed |
| US-20170275243-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2017-09-28 | — | — | US | disclosed |
| EP-3188760-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | Novartis AG (CH) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016037053-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844002-B2 | Lipids and lipid compositions for the delivery of active agents | LRAT, LIPA, LPAR1 | TSHR 584/4885CNR2 2131/4885CNR1 1487/4885 |
| US-20170275243-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | LRAT, LPAR4, LPAR1 | TSHR 591/4885CNR2 2153/4885CNR1 1519/4885 |
| US-10125092-B2 | Lipids and lipid compositions for the delivery of active agents | LRAT, LPAR4, LPAR1 | TSHR 591/4885CNR2 2153/4885CNR1 1519/4885 |
| US-20190002393-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | LRAT, LIPA, LPAR1 | TSHR 584/4885CNR2 2131/4885CNR1 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.